Regeneron reported strong Q4 earnings, initiated dividend program, and authorized share repurchase

From Nasdaq: 2025-02-04 13:48:00

Regeneron Pharmaceuticals, Inc. (REGN) reported Q4 2024 earnings per share of $12.07, exceeding estimates. Total revenues rose 10% to $3.79 billion, driven by collaboration revenues. Shares surged on the news and a new dividend program. Eylea sales in the U.S. declined, but Eylea HD showed growth.

Regeneron’s 2024 results surpassed expectations with revenues of $14.202 billion and EPS of $45.62. The company also initiated a dividend program and authorized a $3.0 billion share repurchase program. Key pipeline updates include positive results for EYLEA HD and regulatory approvals for Dupixent.

Despite Eylea sales decline due to competition, Regeneron is optimistic about Eylea HD uptake. The company’s focus on expanding its oncology portfolio and entering the obesity market is promising. Regeneron currently holds a Zacks Rank #3 (Hold) and continues to show potential for growth and innovation.



Read more at Nasdaq: Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend